Tharimmune, Inc. (THAR) Cash per Single Share

The free cash flow per share dynamics demonstrate the liquidity of Tharimmune, Inc. (THAR), where the 0.19 mark reflects the latest data. Tharimmune, Inc. (THAR) is developing antibodies against hepatic pruritus as it prepares for Phase II. The operating model relies on outsourcing production and testing. The team retains experts through a flexible culture and stock options, minimizing bureaucracy within its research.
Comprehensive metric breakdowns and analytics for Tharimmune Corporation (THAR)

For the biotechnology company Tharimmune, Inc. (THAR), with its extensive network of CDMO facilities, liquidity determines the ability to sustain clinical trials without external financing. This metric is calculated by dividing total cash reserves by the number of shares outstanding. By analyzing cash per share, an investor assesses the business's internal margin of safety. A stable level of this indicator confirms financial autonomy, while a sharp decline signals increasing vulnerability to market shocks.